ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Phase 1

Terminated

Conditions: Wet Age-Related Macular Degeneration

Interventions: Biological: MP0112

First Posted Date: 2010-03-15

Last Posted Date: 2014-05-12

Lead Sponsor: Allergan

Target Recruit Count: 32

Registration Number: NCT01086761

Locations: 🇫🇷
Centre Paradis-Monticelli, Marseille, France
🇫🇷
Centre Rabelais, Lyon, France
🇫🇷
Hopitaux Universitaires, Strasbourg, France

and more 5 locations

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

Phase 2

Completed

Conditions: Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Interventions: Drug: Brimo PS DDS®
Other: Sham

First Posted Date: 2010-03-04

Last Posted Date: 2015-02-20

Lead Sponsor: Allergan

Target Recruit Count: 215

Registration Number: NCT01080209

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Not Applicable

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution
Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution

First Posted Date: 2010-02-17

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 235

Registration Number: NCT01068964

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Phase 2

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost ophthalmic solution 0.005%
Drug: bimatoprost ophthalmic solution 0.015%
Drug: bimatoprost ophthalmic solution 0.03%

First Posted Date: 2010-02-09

Last Posted Date: 2011-12-09

Lead Sponsor: Allergan

Target Recruit Count: 104

Registration Number: NCT01064882

Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema

Phase 1

Terminated

Conditions: Diabetic Macular Edema

Interventions: Biological: MP0112

First Posted Date: 2010-01-05

Last Posted Date: 2014-05-13

Lead Sponsor: Allergan

Target Recruit Count: 18

Registration Number: NCT01042678

Locations: 🇺🇸
Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸
Retina Consultants of Houston, Houston, Texas, United States

and more 1 locations

Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency

Not Applicable

Completed

Conditions: Mid-face Volume Deficiency

Interventions: Device: Cross-linked hyaluronic acid gel

First Posted Date: 2009-12-10

Last Posted Date: 2016-03-09

Lead Sponsor: Allergan

Target Recruit Count: 103

Registration Number: NCT01029535

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

Phase 1

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: AGN208397 intravitreal injection
Drug: dexamethasone intravitreal implant

First Posted Date: 2009-12-08

Last Posted Date: 2014-04-29

Lead Sponsor: Allergan

Target Recruit Count: 121

Registration Number: NCT01027650

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Phase 4

Completed

Conditions: Eyelash Hypotrichosis
Alopecia Areata

Interventions: Drug: bimatoprost ophthalmic solution 0.03%
Drug: Vehicle Sterile Solution

First Posted Date: 2009-12-02

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 71

Registration Number: NCT01023841

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Glycerin and Polysorbate 80 based artificial tear

First Posted Date: 2009-11-10

Last Posted Date: 2015-08-17

Lead Sponsor: Allergan

Target Recruit Count: 288

Registration Number: NCT01010282

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Phase 2

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: AGN-210669 ophthalmic solution, 0.075%
Drug: bimatoprost ophthalmic solution 0.03%
Drug: AGN-210669 ophthalmic solution, 0.1%
Drug: AGN-210669 ophthalmic solution, 0.05%

First Posted Date: 2009-10-26

Last Posted Date: 2013-10-18

Lead Sponsor: Allergan

Target Recruit Count: 165

Registration Number: NCT01001195

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy